Selection of a control group in BMP clinical studies.
Riedel
G
G
Genetics Institute, Inc., Cambridge, MA 02140, USA.
Valentin-Opran
A
A
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D016025:Bone Transplantation; D002986:Clinical Trials as Topic / Q000592:standards*; D006801:Humans; D018579:Patient Selection; D011994:Recombinant Proteins / Q000627:therapeutic use; D013978:Tibial Fractures / Q000628:therapy*; D016212:Transforming Growth Factor beta
C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2